Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital

Detalhes bibliográficos
Autor(a) principal: Simon, Juliana R.
Data de Publicação: 2022
Outros Autores: Pereira, Maria F.B., Marques, Heloisa H., Elias, Adriana M., Sakita, Neusa K., Ferreira, Juliana C.O.A., Precioso, Alexander Roberto, Grisi, Sandra J.F.E., Ferrer, Ana Paula S., Bain, Vera, Silva, Clovis A., Campos, Lúcia M.A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/213562
Resumo: Objectives: To evaluate seroconverted asymptomatic COVID-19 in pediatric Autoimmune Rheumatic Diseases (ARDs) patients and to identify the risk factors related to contagion. Methods: A cross-sectional study was conducted in March 2021, before vaccination of children and adolescents in Brazil, including 77 pediatric ARDs patients, followed at a tertiary hospital and 45 healthy controls, all of them without a previous diagnosis of COVID-19. Data was obtained by a questionnaire with demographic data, symptoms compatible with COVID-19 over the previous year, and contact with people with confirmed COVID-19. Patient's medical records were reviewed to access data regarding disease and current medications. A qualitative immunochromatographic SARS-CoV-2 test was performed on all participants. Results: Patients and controls were similar in terms of female gender (70.1% vs. 57.8%, p = 0.173), age (14 vs. 13 years, p = 0.269) and SARS-CoV-2 positive serology (22% vs. 15.5%, p = 0.481). 80.5% of rheumatic patients were in use of immunosuppressive drugs: 27.3% of them used corticosteroids (33.3% in high doses), and 7.8% on immunobiologicals. No statistical differences were found between positive (n = 17) and negative serology (n = 60) patients regarding demographic/socioeconomic data, contact with people with confirmed COVID-19, use and number of immunosuppressive drugs, use and dose of corticosteroids, use of hydroxychloroquine and immunobiological drugs (p > 0.05). Conclusions: Pediatric rheumatic disease patients were infected at the same rate as healthy ones. Neither the underlying pathology nor its immunosuppressive treatment seemed to interfere with contagion risk.
id USP-19_172c71459c7b3ba9ba58504d2428cf6d
oai_identifier_str oai:revistas.usp.br:article/213562
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospitalCOVID-19 testingRheumatic diseasesImmunosuppressive treatmentSARS-CoV-2SerologyChildrenObjectives: To evaluate seroconverted asymptomatic COVID-19 in pediatric Autoimmune Rheumatic Diseases (ARDs) patients and to identify the risk factors related to contagion. Methods: A cross-sectional study was conducted in March 2021, before vaccination of children and adolescents in Brazil, including 77 pediatric ARDs patients, followed at a tertiary hospital and 45 healthy controls, all of them without a previous diagnosis of COVID-19. Data was obtained by a questionnaire with demographic data, symptoms compatible with COVID-19 over the previous year, and contact with people with confirmed COVID-19. Patient's medical records were reviewed to access data regarding disease and current medications. A qualitative immunochromatographic SARS-CoV-2 test was performed on all participants. Results: Patients and controls were similar in terms of female gender (70.1% vs. 57.8%, p = 0.173), age (14 vs. 13 years, p = 0.269) and SARS-CoV-2 positive serology (22% vs. 15.5%, p = 0.481). 80.5% of rheumatic patients were in use of immunosuppressive drugs: 27.3% of them used corticosteroids (33.3% in high doses), and 7.8% on immunobiologicals. No statistical differences were found between positive (n = 17) and negative serology (n = 60) patients regarding demographic/socioeconomic data, contact with people with confirmed COVID-19, use and number of immunosuppressive drugs, use and dose of corticosteroids, use of hydroxychloroquine and immunobiological drugs (p > 0.05). Conclusions: Pediatric rheumatic disease patients were infected at the same rate as healthy ones. Neither the underlying pathology nor its immunosuppressive treatment seemed to interfere with contagion risk.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2022-09-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21356210.1016/j.clinsp.2022.100110Clinics; Vol. 77 (2022); 100110Clinics; v. 77 (2022); 100110Clinics; Vol. 77 (2022); 1001101980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213562/195644Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessSimon, Juliana R.Pereira, Maria F.B.Marques, Heloisa H.Elias, Adriana M.Sakita, Neusa K.Ferreira, Juliana C.O.A.Precioso, Alexander RobertoGrisi, Sandra J.F.E.Ferrer, Ana Paula S.Bain, VeraSilva, Clovis A.Campos, Lúcia M.A.2023-07-06T13:04:59Zoai:revistas.usp.br:article/213562Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:59Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
title Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
spellingShingle Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
Simon, Juliana R.
COVID-19 testing
Rheumatic diseases
Immunosuppressive treatment
SARS-CoV-2
Serology
Children
title_short Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
title_full Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
title_fullStr Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
title_full_unstemmed Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
title_sort Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital
author Simon, Juliana R.
author_facet Simon, Juliana R.
Pereira, Maria F.B.
Marques, Heloisa H.
Elias, Adriana M.
Sakita, Neusa K.
Ferreira, Juliana C.O.A.
Precioso, Alexander Roberto
Grisi, Sandra J.F.E.
Ferrer, Ana Paula S.
Bain, Vera
Silva, Clovis A.
Campos, Lúcia M.A.
author_role author
author2 Pereira, Maria F.B.
Marques, Heloisa H.
Elias, Adriana M.
Sakita, Neusa K.
Ferreira, Juliana C.O.A.
Precioso, Alexander Roberto
Grisi, Sandra J.F.E.
Ferrer, Ana Paula S.
Bain, Vera
Silva, Clovis A.
Campos, Lúcia M.A.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Simon, Juliana R.
Pereira, Maria F.B.
Marques, Heloisa H.
Elias, Adriana M.
Sakita, Neusa K.
Ferreira, Juliana C.O.A.
Precioso, Alexander Roberto
Grisi, Sandra J.F.E.
Ferrer, Ana Paula S.
Bain, Vera
Silva, Clovis A.
Campos, Lúcia M.A.
dc.subject.por.fl_str_mv COVID-19 testing
Rheumatic diseases
Immunosuppressive treatment
SARS-CoV-2
Serology
Children
topic COVID-19 testing
Rheumatic diseases
Immunosuppressive treatment
SARS-CoV-2
Serology
Children
description Objectives: To evaluate seroconverted asymptomatic COVID-19 in pediatric Autoimmune Rheumatic Diseases (ARDs) patients and to identify the risk factors related to contagion. Methods: A cross-sectional study was conducted in March 2021, before vaccination of children and adolescents in Brazil, including 77 pediatric ARDs patients, followed at a tertiary hospital and 45 healthy controls, all of them without a previous diagnosis of COVID-19. Data was obtained by a questionnaire with demographic data, symptoms compatible with COVID-19 over the previous year, and contact with people with confirmed COVID-19. Patient's medical records were reviewed to access data regarding disease and current medications. A qualitative immunochromatographic SARS-CoV-2 test was performed on all participants. Results: Patients and controls were similar in terms of female gender (70.1% vs. 57.8%, p = 0.173), age (14 vs. 13 years, p = 0.269) and SARS-CoV-2 positive serology (22% vs. 15.5%, p = 0.481). 80.5% of rheumatic patients were in use of immunosuppressive drugs: 27.3% of them used corticosteroids (33.3% in high doses), and 7.8% on immunobiologicals. No statistical differences were found between positive (n = 17) and negative serology (n = 60) patients regarding demographic/socioeconomic data, contact with people with confirmed COVID-19, use and number of immunosuppressive drugs, use and dose of corticosteroids, use of hydroxychloroquine and immunobiological drugs (p > 0.05). Conclusions: Pediatric rheumatic disease patients were infected at the same rate as healthy ones. Neither the underlying pathology nor its immunosuppressive treatment seemed to interfere with contagion risk.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-12
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213562
10.1016/j.clinsp.2022.100110
url https://www.revistas.usp.br/clinics/article/view/213562
identifier_str_mv 10.1016/j.clinsp.2022.100110
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213562/195644
dc.rights.driver.fl_str_mv Copyright (c) 2023 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 77 (2022); 100110
Clinics; v. 77 (2022); 100110
Clinics; Vol. 77 (2022); 100110
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222766988787712